Effectiveness and safety of infliximab for 11 years in a patient with erythrodermic psoriasis and psoriatic arthritis

Trídico, Lívia Arroyo; Antônio, Joäo Roberto; Mathias, Carlos Eduardo; Pozetti, Eurides Maria de Oliveira

doi:10.1590/abd1806-4841.20176565

Cited by 6 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…49,52 Infliximab Infliximab, a chimeric monoclonal antibody, is considered to be a first-line biologic for EP due to its rapid onset. 1,44,52,53,[55][56][57][58][59][60][61][62][63][64][65][66][67][68][69][70] In one multicenter study that included 24 patients, 52 one-third of the patients achieved PASI 75 at week 4 with infliximab treatment. But longterm efficacy is not so promising, as at the same study that only 48% of patients achieved PASI 75 at week 14, 52 and one case reported no further improvement after the sixth infusion of infliximab; the subject's condition was then controlled by administration of etanercept.…”

Section: Mycophenolate Mofetil (Mmf)mentioning

confidence: 99%

Updates on the Treatment of Erythrodermic Psoriasis

Lo¹,

Tsai

2021

PTT

View full text Add to dashboard Cite

Erythrodermic psoriasis (EP) is a rare variant of psoriasis, which is potentially life threatening and often resistant to conventional therapy. Biologics have revolutionized the treatment of plaque-type psoriasis, and shown promise in EP. However, due to the lack of head-to-head studies and the rarity of EP, no high level evidence-based treatment guidelines for EP have been established, and the evidence of treatment of EP is limited to case reports or small case series. Here, we present a narrative review focusing on the up-to-date information for the treatment of EP.

show abstract

Section: Mycophenolate Mofetil (Mmf)mentioning

confidence: 99%

Updates on the Treatment of Erythrodermic Psoriasis

Lo¹,

Tsai

2021

PTT

View full text Add to dashboard Cite

show abstract

“…К провоцирующим факторам относят перенесенные инфекции (4%) и применение лекарственных средств (24%), однако в большом проценте случаев предшествующие факторы выявить не удается [1,2]. В литературе нам встретились описания противоположных клинических случаев: успешного купирования псориатической эритродермии с использованием ИНФ [17][18][19]. Так, I. Belinchon и соавт.…”

unclassified

Difficulties in choosing a biologic disease-modifying anti-rheumatic drug for the treatment of psoriasis and psoriatic arthritis

Марусенко

Везикова

Кондричина

et al. 2019

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

The article presents a clinical observation of a patient with severe psoriasis and psoriatic arthritis. Due to insufficient efficacy of systemic therapy of psoriasis biologic disease-modifying therapy was started, but it was associated with difficulties. Development of erythrodermic form of psoriasis was observed during treatment with infliximab and abatacept was successfully used though it is not registered inRussiafor the treatment of psoriasis.

show abstract